Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 4

Conditions: Hypertension

Treatments: Drug: metoprolol; Drug: carvedilol

Study type: Interventional

Funder types: Industry

Identifiers

NCT00060918

105517/346

Details and patient eligibility

About

To evaluate the effects of two different antihypertensive medications in the drug class of beta-blockers on control of glucose in Type II diabetic patients with high blood pressure.

Sex: All

Ages: 30 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients at screening must be insulin producing Type II diabetics (C peptide positive).
• Must have a history of mild to moderate hypertension (140-179 systolic; 90-1-9 diastolic).
• Must be on stable regimen of ACE (angiotensin converting enzyme) / ARB (angiotensin receptor blocker) treatment alone or in combination with other treatments.
• Patient''s laboratory result for HbA1c must be 6.5 - 8.5 (drug treated) or 6.5 - 7.5 (diet alone).
• Must be on a stable antidiabetic regimen (drug treated or diet alone).

Exclusion criteria

• Patients using beta-blocker therapy.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind